# Paul Mann

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/paul-mann
Canonical HTML page: https://gethealthbrief.com/entity/paul-mann

## Timeline

- **2026**: Commercial Ramp-Up — Targeted date for full-scale commercial isotope production and revenue growth.
- **2026**: QLE Spin-Off Planning — Strategic restructuring to separate enrichment tech from product verticals.
- **2026-02-25**: Emerging Growth Conference — CEO Paul Mann provides update on isotope production and 2026 strategy.
- **2026**: Silicon-28 Shipments — First shipments of high-purity Silicon-28 sent to semiconductor customers.

## Recent coverage (1 stories)

### ASP Isotopes Targets 2026 Commercial Ramp with Silicon-28 and QLE Spin-Off
2026-02-26 12:18:17 · Sentiment: Positive · Impact: 6/10 · Sources: 2

ASP Isotopes CEO Paul Mann outlined a strategic transition to a 2026 commercial ramp-up, highlighting progress in Silicon-28 shipments and a planned spin-off of its Quantum Laser Enrichment division. The company aims to address critical global shortages in medical isotopes and advanced materials for the semiconductor and nuclear sectors.
Full story: https://gethealthbrief.com/story/asp-isotopes-2026-commercial-ramp-qle-spin-off

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.